Advances in Sepsis -an independent journal published by Remedica Medical Education and Publishing Ltd. . The aim is to provide an up-to-date overview of the recent literature compiled by an international team of practicing physicians. Leading articles commissioned by the Editors-in-Chief review new therapeutic techniques and emerging technologies, and news from major international meetings is reported. Editorial control is vested entirely in the Editor-in-Chief and Editorial Board. Any queries regarding the content of the journal should be addressed to:

Subscriptions are free for healthcare professionals. Non-healthcare professionals can subscribe at the rates detailed below.
I am a healthcare professional(free online access, free print in certain territories)
I am not a healthcare professional, and I want free online access
I am not a healthcare professional and I want to pay for a print subscription plus free online access

Title:
First name:
Last name:
Job title:

Institution:
Address 1
Address 2
Address 3
City:
State:
Post / zip code:
Country:

Work Phone Number:
Home Phone Number:
Mobile Number:
Fax Number:

E-mail:
	(used as your login for online access)

I would like to be kept informed of products and services from Remedica Medical Education and Publishing

Advances in Sepsis (ISSN 1472-2445) is published three times per year. Subscriptions are available at the following rates: USA and Canada US$170 per year, Europe EUR130, in all other territories US$170.

In this month's SMART: Crucial Presentations from the Scandinavian Society of Anaesthesiology and Intensive Care Medicine. Research and treatment in pediatric sepsis. Key papers and news from the world media.
Enter SMART >>

Activate your personal SMARTbot today! You choose how SMARTbot will search PubMed. SMARTbot will report back (you decide how often) with the results from your customised searches
Activate your personal SMARTbot today! >>

The material published in Advances in Sepsis is FREE from copyright restriction when used for non-commercial educational purposes.
More information

Advances in Sepsis, SMART™, and SMARTbot™ are supported by educational grants from Eli Lilly and Company, Acute Care. Certain authors and editors may have financial or other relationships with Eli Lilly and Company. Some of the information/data reported here for drugs/devices discussed may differ from information/data contained in the prescribing information approved by regulatory authorities in specific countries. For approved information and uses for drugs/devices discussed, please consult the manufacturer's prescribing information.

This activity has been planned and implemented in accordance with the Essential Areas and Policies of ACCME through the joint sponsorship of the University of Kentucky College of Medicine and Remedica. The University of Kentucky College of Medicine is accredited by the ACCME to provide continuing medical education for physicians. The University of Kentucky is an equal opportunity university.